{ "Short Course Radiation and Chemotherapy for Stage II-III Rectal Cancer", "This study is looking at how well a combination of short-course radiation therapy and chemotherapy works for people with stage II or III rectal cancer. The radiation therapy, called Intensity-Modulated Radiation Therapy (IMRT), uses high-energy X-rays to target cancer cells. The chemotherapy involves several drugs: Capecitabine, Fluorouracil, Leucovorin, and Oxaliplatin, which work in different ways to stop cancer growth. The goal is to see if this treatment can lead to a complete clinical response, potentially reducing the need for surgery and improving quality of life. You may be able to join if you have confirmed stage II or III rectal adenocarcinoma that hasn't spread, are at least 18 years old, and meet certain health criteria. The study aims to enroll 25 participants.", "design": "This is an interventional study, meaning participants will receive a specific treatment. It is a single-arm study with a planned enrollment of 25 participants.", "commitments": "Participants will undergo Intensity-Modulated Radiation Therapy (IMRT) daily for 5 consecutive days, followed by 16 weeks of combination chemotherapy. The primary outcome, complete clinical response, will be measured for up to 5 years.", "compensation": "Not stated in the trial record.", "follow_up": "Participants will be followed to assess complete clinical response for up to 5 years. Other follow-up includes 1-year local recurrence-free survival and 1-year progression-free survival.", }

Study design

Not specified.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.